Adimmune Corp (國光生技), a Taiwanese vaccine developer, said on Tuesday that it is scheduled to list on the Taiwan Stock Exchange (TWSE) on May 3.
According to a prospectus posted on the exchange’s Web site, the company, which was established in 1965 and is capitalized at NT$1.64 billion (US$55.59 million), is planning to issue 19.53 million shares to raise about NT$976.50 million in working capital.
While Adimmune has set a tentative issue price of NT$50 for the shares, market analysts said the actual price is expected to range between NT$40 and NT$43.
Adimmune, which is the only vaccine manufacturer in Asia to have obtained GMP (Good Manufacturing Practice) certification from the EU, specializes in the development of vaccines for influenza, Japanese encephalitis and tetanus.
Adimmune has teamed up with Dutch-based biotech company Crucell, the world’s sixth-largest flu vaccine manufacturer, for technological cooperation, while it has also partnered with Japan’s largest flu vaccine developer, the Kitasato Institute.
Crucell is one of the company’s majority shareholders, with an 11.39 percent stake, according to the prospectus.
Adimmune chairman Steve Chan (詹啟賢) told investors that the company completed animal testing for an H5N1 avian flu vaccine at the end of last year and is expected to begin human testing this year.
In addition, Chan said the company’s enterovirus 71 vaccine, which is undergoing clinical trials, is scheduled to hit the market in 2017, while a dengue fever vaccine is expected to be launched in 2019.
Last year, the company sold about 1.5 million flu vaccine doses in Taiwan, taking a 55 percent share of the domestic flu vaccine market. The company expects its market share to fall to about 50 percent this year.
In addition, it anticipates it will be granted permits to sell flu vaccine in China at the end of this year at the earliest.
Adimmune posted NT$290 million in sales last year, but incurred a NT$2.87 net loss per share because of an unsatisfactory capacity utilization rate.
However, on the back of rising production, its capacity utilization rate is expected to range between 70 percent and 80 percent in the second half of this year and it is likely to exceed 90 percent next year, which will improve its bottom line, the company said.
Taiwan’s technology protection rules prohibits Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) from producing 2-nanometer chips abroad, so the company must keep its most cutting-edge technology at home, Minister of Economic Affairs J.W. Kuo (郭智輝) said yesterday. Kuo made the remarks in response to concerns that TSMC might be forced to produce advanced 2-nanometer chips at its fabs in Arizona ahead of schedule after former US president Donald Trump was re-elected as the next US president on Tuesday. “Since Taiwan has related regulations to protect its own technologies, TSMC cannot produce 2-nanometer chips overseas currently,” Kuo said at a meeting of the legislature’s
TECH WAR CONTINUES: The suspension of TSMC AI chips and GPUs would be a heavy blow to China’s chip designers and would affect its competitive edge Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s biggest contract chipmaker, is reportedly to halt supply of artificial intelligence (AI) chips and graphics processing units (GPUs) made on 7-nanometer or more advanced process technologies from next week in order to comply with US Department of Commerce rules. TSMC has sent e-mails to its Chinese AI customers, informing them about the suspension starting on Monday, Chinese online news outlet Ijiwei.com (愛集微) reported yesterday. The US Department of Commerce has not formally unveiled further semiconductor measures against China yet. “TSMC does not comment on market rumors. TSMC is a law-abiding company and we are
FLEXIBLE: Taiwan can develop its own ground station equipment, and has highly competitive manufacturers and suppliers with diversified production, the MOEA said The Ministry of Economic Affairs (MOEA) yesterday disputed reports that suppliers to US-based Space Exploration Technologies Corp (SpaceX) had been asked to move production out of Taiwan. Reuters had reported on Tuesday last week that Elon Musk-owned SpaceX had asked their manufacturers to produce outside of Taiwan given geopolitical risks and that at least one Taiwanese supplier had been pushed to relocate production to Vietnam. SpaceX’s requests place a renewed focus on the contentious relationship Musk has had with Taiwan, especially after he said last year that Taiwan is an “integral part” of China, sparking sharp criticism from Taiwanese authorities. The ministry said
US President Joe Biden’s administration is racing to complete CHIPS and Science Act agreements with companies such as Intel Corp and Samsung Electronics Co, aiming to shore up one of its signature initiatives before US president-elect Donald Trump enters the White House. The US Department of Commerce has allocated more than 90 percent of the US$39 billion in grants under the act, a landmark law enacted in 2022 designed to rebuild the domestic chip industry. However, the agency has only announced one binding agreement so far. The next two months would prove critical for more than 20 companies still in the process
RSS